STF-31

STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC₅₀ of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells^[1][2]. IC50 & Target:IC50: 1 μM (GLUT1)^[1] In Vitro:STF-31 (0.01-10 μM; 10 days) is specifically toxic to RCC4 cells, whereas RCC4/VHL cells are relatively unaffected. RCC4/VHL cells treated with STF-31 (5 μM; 10 days) largely recovery, whereas RCC4 cells under the same conditions does not^[1].
STF-31 (1.25-5 μM; 3 days) does not induce autophagy, apoptosis, or DNA damage. STF-31 causes a necrotic cell death^[1].
STF-31 reduces the efferocytosis of wild type and SLC2A1-overexpressing LR73 cells^[4]. In Vivo:STF-31 (10 mg/kg; i.p.; twice daily for 2 days, followed by once daily for another 3 days) does not affect normal mice body weight, behavior, and ERG responses. STF-31 reduces light-induced CX3CR1^gfp/+ mice microglial activation and retinal degeneration^[3].
STF-31 (10 mg/kg; i.p.) promotes accumulation of necrotic thymocytes after Dexamethasone-induced apoptosis in vivo^[4].